Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > Nanosphere Recalls ‘Very Small Number’ of Verigene Assays Due to ‘Aberrant Result’

April 23rd, 2008

Nanosphere Recalls ‘Very Small Number’ of Verigene Assays Due to ‘Aberrant Result’

Abstract:
Nanosphere in February recalled an unspecified number of its Verigene warfarin metabolism assay cartridges due to faulty results, nearly five months after the US Food and Drug Administration approved the tests, the company disclosed earlier this month.

The recall of the assay, which was the first FDA-approved genetic test of its kind, involved a "very small number of warfarin assay cartridges that Nanosphere wanted to recover to test for the possibility of reproducing an uncharacteristic result," a company spokesperson told Pharmacogenomics Reporter this week.

In an announcement earlier this month, the FDA said that Nanosphere informed the agency of the recall in letters dated Feb. 25. According to the announcement, Nanosphere recalled eight lots of its warfarin metabolism nucleic acid-test cartridge (part number 20-006-002). The FDA designated this a Class II recall, which means that "there is either a possibility that the device will cause temporary or reversible health problems, or there is a remote chance that the device will cause serious health problems."

Source:
pgxreporter.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project